-
Mashup Score: 0STAT Expert Advantage - 4 year(s) ago
A Deep Dive Into Phenylketonuria (PKU) – Exploring New Approaches by BioMarin, Homology, Rubius, and Moderna
Source: Slingshot InsightsCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 4STAT Expert Advantage - 4 year(s) ago
A Deep Dive Into Phenylketonuria (PKU) – Exploring New Approaches by BioMarin, Homology, Rubius, and Moderna
Source: Slingshot InsightsCategories: General Medicine News, Latest HeadlinesTweet-
From Moderna’s mRNA therapy to Homology’s gene therapy, a number of competing therapies for phenylketonuria, a metabolic disorder, are emerging. Join STAT Expert Advantage for a discussion of what the treatment landscape might look like. https://t.co/ZWYp0nCpNU https://t.co/MnueigtTTS
-
-
Mashup Score: 0STAT Expert Advantage - 4 year(s) ago
After a positive FDA panel for Aimmune’s and FDA decision looming, we will discuss the commercial potential of Palforzia. NOTE: Call will have a proprietary survey, run by SI, of high volume pediatric allergists/immunologists available.
Source: Slingshot InsightsCategories: General Medicine News, Latest HeadlinesTweet-
Join STAT's @adamfeuerstein for this month’s STAT Expert Advantage call titled: “The commercial potential of Palforzi.” If you’ve been following $AIMT and $DBVT then this is a must-listen. Join here: https://t.co/s9DxTky7l4 #STATExpertAdvantage https://t.co/MDld1s00AH
-
-
Mashup Score: 0STAT Expert Advantage - 4 year(s) ago
A Look at the Breast Cancer Landscape: An Expert’s Take on the Newly Approved Daiichi Sankyo Drug, ENHERTU, SGEN’s tucatinib, & the Role of IO therapy
Source: Slingshot InsightsCategories: General Medicine News, Latest HeadlinesTweet-
IN ONE HOUR Join STAT Expert Advantage to access our July conference call exploring the breast cancer drug pipeline. Sign up now to listen in: https://t.co/lFXtnrukLo #breastcancer #STATExpertAdvantage https://t.co/BdfualHXPq
-
-
Mashup Score: 0STAT Expert Advantage - 4 year(s) ago
A Look at the Breast Cancer Landscape: An Expert’s Take on the Newly Approved Daiichi Sankyo Drug, ENHERTU, SGEN’s tucatinib, & the Role of IO therapy
Source: Slingshot InsightsCategories: General Medicine News, Latest HeadlinesTweet-
Join STAT Expert Advantage to access our July conference call exploring the breast cancer drug pipeline. Sign up here to listen in: https://t.co/uEU8rMx8kZ #STATExpertAdvantage #breastcancer #Cancer https://t.co/01YCk9i3Ej
-
-
Mashup Score: 0STAT Expert Advantage - 4 year(s) ago
A Look at the Breast Cancer Landscape: An Expert’s Take on the Newly Approved Daiichi Sankyo Drug, ENHERTU, SGEN’s tucatinib, & the Role of IO therapy
Source: Slingshot InsightsCategories: General Medicine News, Latest HeadlinesTweet-
Join STAT Expert Advantage to access our July conference call exploring the breast cancer drug pipeline. Sign up here: https://t.co/yULhtlZZE3 #STATExpertAdvantage #breastcancer https://t.co/voE8CNzH3i
-
-
Mashup Score: 5STAT Expert Advantage - 4 year(s) ago
Exploring gene therapy treatments in the hemophilia space including those from BioMarin, Spark Therapeutics, and UniQure
Source: Slingshot InsightsCategories: General Medicine News, Latest HeadlinesTweet-
What separates the gene therapies for hemophilia from BioMarin, Roche, & Sangamo Therapeutics? Join STAT Expert Advantage to listen in as @damiangarde and Dr. Guy Young discuss on this month’s call. Your spot here: https://t.co/lggdimJHJR $BMRN $RHHBY $SGMO #STATExpertAdvantage https://t.co/cJOwAkKTIL
-
-
Mashup Score: 0STAT Expert Advantage - 4 year(s) ago
Exploring gene therapy treatments in the hemophilia space including those from BioMarin, Spark Therapeutics, and UniQure
Source: Slingshot InsightsCategories: General Medicine News, Latest HeadlinesTweet-
What separates the gene therapies for hemophilia from BioMarin, Roche, & Sangamo Therapeutics? Join STAT Expert Advantage to listen in as @damiangarde and Dr. Guy Young discuss on this month’s call. Your spot here: https://t.co/SO7Wlcjv6d $BMRN $RHHBY $SGMO #STATExpertAdvantage https://t.co/cKavMEpLYi
-
-
Mashup Score: 0STAT Expert Advantage - 4 year(s) ago
Exploring gene therapy treatments in the hemophilia space including those from BioMarin, Spark Therapeutics, and UniQure
Source: Slingshot InsightsCategories: General Medicine News, Latest HeadlinesTweet-
What separates the gene therapies for hemophilia from BioMarin, Roche, and Sangamo Therapeutics? Join STAT Expert Advantage to listen in as @damiangarde & Dr. Guy Young discuss on this month’s call. Your spot here: https://t.co/Ks9jqAdram $BMRN $RHHBY $SGMO #STATExpertAdvantage https://t.co/cR1IH5fDw2
-
-
Mashup Score: 3STAT Expert Advantage - 4 year(s) ago
Exploring gene therapy treatments in the hemophilia space including those from BioMarin, Spark Therapeutics, and UniQure
Source: Slingshot InsightsCategories: General Medicine News, Latest HeadlinesTweet-
What separates the gene therapies for hemophilia from BioMarin, Roche, & Sangamo Therapeutics? Join STAT Expert Advantage to listen as @damiangarde & Dr. Guy Young discuss on this month’s call. Save your spot here: https://t.co/u508oEoZBW $BMRN $RHHBY $SGMO #STATExpertAdvantage https://t.co/RsDnpZTQq1
-
TODAY Join our STAT Expert Advantage call exploring the treatment landscape for the metabolic disorder phenylketonuria, or PKU. Save your spot here: https://t.co/mecHP13yKS #STATExpertAdvantage https://t.co/Ypdi1vV6ql